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PNebivolol Exerts Beneficial Effects on Endothelial
Function, Early Endothelial Progenitor Cells,
Myocardial Neovascularization, and Left Ventricular
Dysfunction Early After Myocardial Infarction
Beyond Conventional 1-Blockade
Sajoscha A. Sorrentino, MD,*† Carola Doerries, MD,*‡ Costantina Manes, MD,*‡
Thimoteus Speer, MD,‡ Chantal Dessy, PHD,§ Irina Lobysheva, PHD,§ Wazma Mohmand, MD,*
Razma Akbar, MD,* Ferdinand Bahlmann, MD, PHD,† Christian Besler, MD,*‡ Arnd Schaefer, MD,*
Denise Hilfiker-Kleiner, PHD,* Thomas F. Lüscher, MD,‡ Jean-Luc Balligand, MD, PHD,§
Helmut Drexler, MD,* Ulf Landmesser, MD*‡
Hannover, Germany; Zurich, Switzerland; and Brussels, Belgium
Objectives The aim of this study was to investigate whether nebivolol has added effects on left ventricular (LV) dysfunction
and remodeling early after myocardial infarction (MI) beyond its 1-receptor–blocking properties.
Background Nebivolol is a third-generation selective 1-adrenoreceptor antagonist that stimulates endothelial cell nitric oxide
(NO) production and prevents vascular reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
activation. Both endothelial NO synthase–derived NO production and NADPH oxidase activation are critical mod-
ulators of LV dysfunction early after MI.
Methods Mice with extensive anterior MI (n  90) were randomized to treatment with nebivolol (10 mg/kg/day),
metoprolol-succinate (20 mg/kg/day), or placebo for 30 days starting on day 1 after surgery.
Results Infarct size was similar among the groups. Both 1-adrenergic receptor antagonists caused a similar decrease in
heart rate. Nebivolol therapy improved endothelium-dependent vasorelaxation and increased early endothelial
progenitor cells 4 weeks after MI compared with metoprolol and placebo. Nebivolol, but not metoprolol, inhib-
ited cardiac NADPH oxidase activation after MI, as detected by electron spin resonance spectroscopy analysis.
Importantly, nebivolol, but not metoprolol, improved LV dysfunction 4 weeks after MI (LV ejection fraction:
nebivolol vs. metoprolol vs. placebo: 32  4% vs. 17  6% vs. 19  4%; nebivolol vs. metoprolol: p  0.05) and
was associated with improved survival 4 weeks post-MI compared with placebo. Nebivolol had a significantly
more pronounced inhibitory effect on cardiomyocyte hypertrophy after MI compared with metoprolol.
Conclusions Nebivolol improves LV dysfunction and survival early after MI likely beyond the effects provided by conventional 1-
receptor blockade. Nebivolol induced effects on NO-mediated endothelial function, early endothelial progenitor cells
and inhibition of myocardial NADPH oxidase likely contribute to these beneficial effects of nebivolol early after MI.
(J Am Coll Cardiol 2011;57:601–11) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.037(
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tions, in particular, stimulating
endothelial cell nitric oxide (NO)
production (2– 4), which is
thought to be mediated by 3-
receptor activation (5–7), and by
interaction with the estrogen re-
ceptor (8). The release of the
endothelium-derived relaxing
factor NO has been suggested to
mediate vasodilatory properties
of nebivolol because nebivolol-
induced vasodilation is almost
completely blocked by inhibi-
tors of NO synthase (3). More-
over, administration of nebivolol
has been shown to prevent
hypercholesterolemia-induced
uncoupling of endothelial NO
synthase (eNOS) (9) and to re-
store NO availability in endothe-
ial cells obtained from black Americans (10). Furthermore,
ebivolol has been suggested to exert systemic antioxidant
ffects (11) and to inhibit inflammatory cell reduced nico-
inamide adenine dinucleotide phosphate (NADPH) oxi-
ase activation (9) and vascular NADPH oxidase activation
n response to angiotensin II (12).
Importantly, accumulating evidence suggests a critical
ole of both eNOS-derived NO availability (13–15) and
ADPH oxidase activation for left ventricular (LV) dys-
unction and cardiomyocyte hypertrophy early after MI
16–18). In this respect, we recently observed that statins
mprove endothelium-dependent vasodilation, LV dysfunc-
ion, and survival after experimental MI that was critically
ependent on their effect on eNOS, suggesting that in-
reased eNOS-derived NO production may exert beneficial
ffects on LV dysfunction and survival after MI (13,14,19).
urthermore, endothelium- or cardiomyocyte-targeted
verexpression of eNOS resulted in improved LV function
fter MI (13,19). In contrast, suppression of eNOS-
ependent NO production resulted in increased LV dys-
unction (15), reduced myocardial neovascularization (20),
nd impaired mobilization of early endothelial progenitor
ells (EPCs) (14,19).
In addition, we and others have observed that prevention
f NADPH oxidase activation after MI improved LV
ysfunction after MI, supporting the concept that NADPH
xidase activation contributes importantly to LV dysfunc-
ion early after MI (16,17).
The present study was therefore designed to examine the
ffect of nebivolol therapy compared with metoprolol-
uccinate or placebo on endothelium-dependent, NO-
ediated vasodilation, early EPC mobilization, and myo-
ardial NADPH oxidase activation as analyzed by electron
esonance spectroscopy (ESR) early after MI. Moreover, we
Abbreviations
and Acronyms
CSA  cross-sectional area
eNOS  endothelial nitric
oxide synthase
EPC  endothelial
progenitor cell
ESR  electron spin
resonance
HAEC  human aortic
endothelial cell
KOH  potassium
hydroxide
LV  left ventricular
MI  myocardial infarction
NADPH  reduced
nicotinamide adenine
dinucleotide phosphate
NO  nitric oxidexamined the effect of nebivolol and metoprolol-succinate herapy on LV dysfunction, survival and cardiomyocyte
ypertrophy early after MI.
ethods
nimals, MI, and experimental protocol. The local
ommittee on animal research approved all procedures
nvolving experimental animals, and all procedures were
erformed in accordance with the Guide for the Care and
se of Laboratory Animals as adopted by the U.S.
ational Institutes of Health.
In male C57BL/6J mice, age 14 to 16 weeks, MI was
nduced by permanent ligation of the left anterior descend-
ng coronary artery as described previously (14,16). On the
rst day, 24 h after MI, these mice were randomized into 3
roups (30 in each group): 1) treatment with nebivolol (10
g kg1 day1); 2) metoprolol-succinate (20 mg kg1
ay1); or 3) inert vehicle given orally via gastric gavage for
0 days starting on day 1 after surgery. Sham-operated mice
n  30) served as controls. The doses of nebivolol and
etoprolol-succinate were used to achieve similar reduc-
ions in heart rate (as observed in preliminary experiments).
Furthermore, in additional experiments, MI was induced
n eNOS/ mice that were randomized on day 1 to
ebivolol or vehicle therapy (n  10 in each group) using
he previously mentioned dose. Sham-operated eNOS/
ice (n  10) served as controls.
tudies of endothelium-dependent, NO-mediated vaso-
elaxation. Endothelium-dependent, NO-mediated vaso-
elaxation in response to acetylcholine and endothelium-
ndependent relaxation in response to nitroglycerin were
tudied in ring segments of thoracic aortas, as described
reviously (14,21,22). Notably, it has been shown that
cetylcholine responses are lacking in eNOS-deficient mice
21,23), which indicates that these responses are dependent
n eNOS.
arly EPC culture assay. Early EPCs were cultured as
escribed in detail previously (14,24–26). In brief, mono-
uclear cells were isolated from 1 ml of peripheral blood by
ensity gradient centrifugation with Histopaque (Sigma,
unich, Germany) (27), seeded on tissue culture cover-
lips (9  105 cells) coated with rat vitronectin (Sigma) in
ndothelial basal medium (endothelial growth medium-2
V, Clonetics, Lonza, Basel, Switzerland) and supple-
ented with endothelial growth medium-2 MV single
uots (containing fetal bovine serum, human vascular en-
othelial growth factor A, human fibroblast growth factor
, human epidermal growth factor, insulin-like growth
actor-1, and ascorbic acid in appropriate amounts). After 4
ays in culture, nonadherent cells were removed by washing
ith phosphate-buffered saline. The cell culture was main-
ained through day 7, and fluorescence chemical detection
as performed. To detect the uptake of 1,1=-dioctadecyl-
,3,3=,3=-tetramethylindocarbocyanine–labeled acetylated
DL (acLDL-DiI), Molecular Probes, Invitrogen, Carls-
ad, California), cells were incubated with acLDL-DiI (6
g/ml, 37°C, 2 h). Cells were then fixed with 1% parafor-
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February 1, 2011:601–11 Beneficial Effects of Nebivolol Post-MI Beyond 1-Blockadealdehyde for 10 min and incubated with fluorescein-
abeled Griffonia simplicifolia lectin I (BS-1 lectin, Vector
aboratories, Burlingame, California) for 1 h. After being
tained, samples were analyzed with an inverted fluores-
ence microscope (Leica, Wetzlar, Germany), and double-
tained cells for both BS-1 lectin and acLDL-DiI were
ounted as early EPCs in at least 4 randomly selected
igh-power fields (28).
istomorphometric analysis and immunohistochemistry.
issue morphometry was performed in a blinded fashion with
he Quantimet 500MC (Leica, Cambridge, England) digital
mage analyzer. After in situ fixation, LV tissue slices were
mbedded in paraffin and cut into 4-m sections, as described
reviously (16,29). Mean cardiomyocyte cross-sectional area
CSA) or length and infarct size were determined in hema-
oxylin-eosin–stained sections or sections stained with antibod-
es recognizing wheat germ agglutinin to visualize myocyte
oundaries (WGA) (Vector Laboratories) using the digital
mage analyzer as described previously (29–32). Nuclei were
tained with 4,6-diamino-2-phenylindole. For measurements
f the cardiomyocyte CSA or cardiomyocyte length, only
ross-gated cardiomyocytes and respectively longitudinally sec-
ioned cardiomyocytes were analyzed. Furthermore, the length
f cardiomyocytes isolated from in situ formalin-fixed LV
issue was measured using the potassium hydroxide (KOH)
ethod as described in detail previously (33). In brief, LV
amples were cut into small pieces, placed overnight in a
2.5-mol/L KOH solution and transferred to phosphate
uffer. Samples were then mixed using a vortexer, centrifuged,
nd resuspended in 10% formaldehyde-phosphate buffer. Nu-
lei were stained by Mayer’s hemalaum solution to differentiate
etween cell fragments and intact myocytes. Myocyte length
50 structurally intact myocytes per sample) was determined by
sing an Olympus BX51 microscope (Olympus, Volketswil,
witzerland) and the software program Analysis 5.0 (Soft
maging System, Muenster, Germany).
For immunohistochemistry analysis of capillary density,
id-LV specimens were obtained and capillary density was
etermined, as described in detail previously (14). Sections
ere immunostained with the antiplatelet and endothelial
ell adhesion molecule-1 (CD31) rabbit polyclonal antibody
H-300, Santa Cruz Biotechnology, Heidelberg, Germany)
nd detection of the primary antibody was performed using
he avidin-biotin-peroxidase labeling system. Counterstain-
ng was performed with hematoxylin, and results are ex-
ressed as capillaries per cardiomyocytes. At least 6 high-
ower fields of cross-sectioned areas per infarct border zone
ere examined by an investigator blinded to the treatment
roup.
chocardiographic measurements. Echocardiographic
nalysis was performed with the mice under light anesthesia
ketamine 100 mg/kg, xylazine 1.25 mg/kg, and atropine
.6 mg/kg intraperiotoneally), and spontaneous respiration
as provided with a commercially available ultrasound
ystem (ATL5000 CV, Philips Medical System, Bothell,
ashington) with a linear 15-MHz high-frequency trans- aucer, as described previously (14,16). The investigator
A.S.) was blinded to the experimental group.
easurement of myocardial NADPH oxidase activity by
SR spectroscopy analysis. Activity of NADPH oxidase
as determined in remote LV myocardium (50 g protein)
y ESR spectroscopy, as described previously by using the
pin probe 1-hydroxy-3 carboxypyrrolidine (CP-H, Axxora,
ruenberg, Germany) and a MiniScope ESR spectrometer
Magnettech, Berlin, Germany) (16,34). The ESR settings
ere the following: field center, 3,367.67 G; field sweep
idth, 108.92 G; microwave frequency, 9.82 GHz; micro-
ave power, 20 mW; magnetic field modulation frequency,
00 kHz; modulation amplitude, 2 G. The intensity of ESR
pectra was quantified after subtraction of the ESR signal of
amples without NADPH (obtained for each sample).
easurement of superoxide production in human aortic
ndothelial cells (HAECs) by ESR spectroscopy analysis.
AECs purchased from Lonza were grown according to
tandard procedures. Serum-starved HAECs were exposed
o metoprolol (10 mol/l), nebivolol (10 mol/l), or the
olvent after 60-min pre-incubation with various pharma-
ological modulators (i.e., bupranolol 10 mol/l or nadolol
0 mol/l), as described in detail previously (6).
Superoxide production in HAECs in response to 24-h
ngiotensin II stimulation was measured by ESR spectros-
opy and the spin trap CP-H, as described in detail
reviously (16,34).
lood pressure measurements. Systolic blood pressure
as measured by a computerized noninvasive tail cuff system
Blood Pressure Analysis System BP-200, Visitech Systems,
pex, North Carolina), as described previously (14,22).
tatistical analysis. All data are expressed as mean 
EM. Statistical analysis was performed using analysis of
ariance followed by the Newman-Keuls multiple compar-
son test. For the comparison of 2 groups (eNOS-deficient
ice), the 2-tailed, unpaired Student t test was used.
omparison of survival was performed using Kaplan-Meier
nalysis and the log-rank test. A p value 0.05 was
onsidered statistically significant. Data were analyzed by
sing GraphPad Prism 4.03 (GraphPad Software, San
iego, California).
esults
ffect of nebivolol and metoprolol-succinate treatment
n endothelium-dependent, NO-mediated vasodilation
fter MI. In sham-operated mice, acetylcholine produced
ndothelium-dependent relaxations of 93  10%. These
esponses were substantially impaired in aortas of wild-type
ice 4 weeks after MI (21  4%; p  0.05) (Fig. 1A).
ebivolol treatment markedly improved endothelium-
ependent vasodilation in response to acetylcholine in mice
fter MI (55  7%; p  0.05 vs. placebo), whereas
etoprolol had no effect (21  3%, p  NS vs. vehicle)
Fig. 1A). In contrast, endothelium-independent vasodila-
ion in response to nitroglycerin was not impaired in mice
fter MI and was not changed by nebivolol or metoprolol
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Beneficial Effects of Nebivolol Post-MI Beyond 1-Blockade February 1, 2011:601–11reatment (Fig. 1B). In eNOS/ mice, no endothelium-
ependent vasodilation in response to acetylcholine was
bserved, indicating that these responses are dependent on
NOS (data not shown).
ffect of nebivolol and metoprolol-succinate treatment
n early EPCs after MI. Increasing evidence suggests that
NOS activation plays a critical role in the mobilization of
arly EPCs (14,35). However, it is not known whether the
umber of early EPCs is altered by -blocker treatment in
he presence of an ischemic stimulus. Notably, nebivolol
herapy markedly increased early EPCs compared with
lacebo (Figs. 2A and 2B). In contrast, metoprolol-
uccinate treatment had no significant effect on early EPC
umbers compared with vehicle (Figs. 2A and 2B). As
hown in Figure 2D, nebivolol therapy did not change early
PC numbers in eNOS/ mice, suggesting that this
esponse is dependent on eNOS.
ffect of nebivolol and metoprolol-succinate treatment
n myocardial capillary density after MI. The effect of
ebivolol and metoprolol-succinate therapy on capillary
ensity after MI was examined in at least 6 representative
igh-power fields of the infarct border zone. Nebivolol, but
ot metoprolol-succinate, therapy resulted in a significant
ncrease in capillary density in the infarct border zone in
ild-type mice after MI (Fig. 2C). In contrast, nebivolol
herapy had no effect on capillary density in eNOS/ mice
fter MI (Fig. 2E).
SR spectroscopic analysis of myocardial NADPH oxidase
ctivity after MI. NADPH oxidase activation has been
hown to play a pivotal role in cardiomyocyte hypertro-
hy and LV dysfunction after MI (16,17). Furthermore,
Figure 1 Endothelium-Dependent and -Independent Vasorelaxat
(A) Endothelium-dependent, nitric oxide (NO)–mediated vasodilation in response to
mice 4 weeks after surgery. The significance test between groups shows a compa
response to nitroglycerin in sham-operated and vehicle-, metoprolol-, and nebivololebivolol has been shown to inhibit vascular NADPH sxidase activation in response to hyperlipidemia (9). We
herefore examined the effect of nebivolol and metoprolol-
uccinate therapy on myocardial NADPH oxidase activity
y using ESR spectroscopy. NADPH oxidase activity in LV
emote myocardium was markedly increased after MI
Figs. 3A and 3B). After 30 days of treatment with
ebivolol, but not with metoprolol, myocardial NADPH
xidase activity was substantially reduced as assessed by
SR spectroscopy, indicating a suppression of myocardial
ADPH oxidase activation by nebivolol after MI (Figs. 3A
nd 3B).
ffect of nebivolol and metoprolol on cardiomyocyte
ypertrophy and cardiomyocyte length after MI. After
I, we observed cardiomyocyte hypertrophy as indicated by
n increased LV weight/body weight ratio and increased
ardiomyocyte length and CSA in the remote myocardium
Fig. 4, Table 1). Although both -blocker therapies
ecreased cardiomyocyte hypertrophy after MI, treatment
ith nebivolol had a significantly more pronounced inhib-
tory effect on LV weight/body weight and cardiomyocyte
SA compared with metoprolol (p 0.05 vs. metoprolol in
ig. 4A, p 0.001 vs. metoprolol in Table 1). In eNOS/
ice, the response of nebivolol therapy on LV mass and
ypertrophy was attenuated compared with wild-type mice
Table 2), suggesting that this effect is at least partly
ependent on eNOS.
Our data suggest that cardiomyocyte lengthening con-
ributed to the observed LV weight/body mass differences
fter MI (i.e., measurements of cardiomyocyte length of
solated cardiomyocytes by using the KOH method indi-
ated an increase in cardiomyocyte length after MI that was
lcholine (Ach) in sham-operated and vehicle-, metoprolol-, and nebivolol-treated
t the highest concentration. (B) Endothelium-independent vasorelaxation in
d mice 4 weeks after surgery.ion
acety
rison a
-treateignificantly attenuated by both -blockers after MI (Fig. 4B).
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February 1, 2011:601–11 Beneficial Effects of Nebivolol Post-MI Beyond 1-Blockadehe measurements of cardiomyocyte length of in situ fixed
ardiac samples indicated a cardiomyocyte lengthening after
I that was reduced to a significantly greater extent by
ebivolol compared with metoprolol-succinate therapy
Figs. 4C and 4D). A similar trend for a more pronounced
ffect of nebivolol therapy on cardiomyocyte length was
bserved by measurements of isolated cardiomyocytes using
he KOH method that, however, did not reach statistical
ignificance (Fig. 4B).
ffect of nebivolol and metoprolol on LV dysfunction
fter MI. LV ejection fraction was substantially decreased
weeks after MI compared with sham-operated animals.
otably, nebivolol, but not metoprolol, therapy significantly
mproved fractional shortening and LV ejection fraction 4
eeks after MI (Figs. 5A to 5C, Table 1), suggesting that
ebivolol therapy is associated with an early beneficial effect
n LV function after MI. This effect of nebivolol therapy
as not observed in eNOS/ mice after MI, suggesting
hat the eNOS is involved in this effect (Figs. 5D and 5E,
able 2).
urvival post-MI. Nebivolol therapy was associated with a
Figure 2 Early EPCs and Capillary Density
(A) Early endothelial progenitor cells (EPCs) per high-power field in sham-operated
(representative photographs are shown in B). (C) Capillary density in the left ventr
after surgery. (D) Early EPCs per high-power field in vehicle- and nebivolol-treated e
illary density in the left ventricular infarct border zone in vehicle- and nebivolol-treaignificantly improved survival at 4 weeks after MI compared sith vehicle therapy (p  0.05 vs. vehicle). The impact of
etoprolol was not statistically significant (Fig. 6).
SR spectroscopic analysis of superoxide production in
AECs. The effect of blockade of specific -adrenoreceptors
as tested on endothelial superoxide production in response to
ngiotensin II, known to be dependent on NADPH oxidase
ctivation (36). As shown in Figure 7, pre-treatment of
AECs with the 1-2-blocker nadolol (10 mol/l) had no
ffect on nebivolol-induced reduction of endothelial super-
xide production, whereas the complete 1-2-3-blocker bu-
ranolol prevented nebivolol’s effect on endothelial super-
xide production in response to angiotensin II, suggesting
hat the antioxidant effect of nebivolol was mediated via the
3-receptor.
nfarct size, heart rate, and blood pressure. Infarct size
id not differ between the treatment groups (Tables 1 and 2).
eart rate and blood pressure were similarly decreased by
ither -blocker treatment (Table 1).
iscussion
he present study demonstrates that nebivolol, a 1-
hicle-, metoprolol-, and nebivolol-treated mice 4 weeks after surgery
infarct border zone in vehicle-, metoprolol-, and nebivolol-treated mice 4 weeks
elial nitric oxide synthase (eNOS)–deficient mice 4 weeks after surgery. (E) Cap-
OS-deficient mice 4 weeks after surgery (n  7 to 8).and ve
icular
ndoth
ted eNelective adrenoreceptor antagonist with eNOS-stimulating
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Beneficial Effects of Nebivolol Post-MI Beyond 1-Blockade February 1, 2011:601–11roperties, attenuates LV dysfunction and cardiomyocyte
ypertrophy early after MI, and is associated with improved
urvival, which likely goes beyond the effects of conventional
-blockade. These effects of nebivolol therapy on LV
ysfunction and cardiomyocyte hypertrophy early after MI
ere largely blunted in eNOS-deficient mice, supporting a
ritical role of eNOS in this respect. Thus, the present study
upports the notion that beneficial effects of conventional
-blockade can be increased by cardiac NO-dependent
ctions, which may be related, at least in part, to activation
f 3-receptors by nebivolol that may increase eNOS-
ependent NO availability both, by preventing NADPH
xidase activation and stimulation of eNOS.
Our present observations provide novel mechanistic in-
ights concerning the early beneficial effects of nebivolol on
V function post-MI. Nebivolol therapy exerted a beneficial
ffect on endothelium-dependent, NO-mediated vasodila-
ion, early EPC mobilization, and myocardial neovascular-
zation after MI, likely independent of its 1-receptor–
locking effects because it was not observed with the
1-selective adrenoreceptor antagonist metoprolol. Further-
ore, in contrast to metoprolol-succinate, nebivolol inhib-
ted myocardial NADPH oxidase activation after MI.
oreover, our data suggest that the ability of nebivolol to
ecrease angiotensin II–induced NADPH oxidase–
ependent superoxide production is dependent on 3-
eceptor activation. In contrast to the neutral effect of
1-2-blockade by nadolol, the 1-2-3-blocker bupranolol
ignificantly inhibited nebivolol’s effect on superoxide pro-
uction.
Several studies have firmly established the beneficial
ffects of conventional -blockers on LV remodeling pro-
esses post-MI (37). However, although prolonged
-blocker therapy has been shown to improve LV function
n patients with chronic heart failure and LV systolic
ysfunction, the present study suggests that nebivolol exerts
beneficial effect on LV function and survival early after MI
ikely beyond 1-blockade that may be mediated by preven-
ion of NADPH oxidase activation and enhanced eNOS-
ependent NO availability.
Nebivolol is a third-generation highly selective 1-
drenoreceptor blocker. There is evidence that nebivolol, in
ddition to its 1-adrenoreceptor blocking effects, can
timulate endothelial NO production, which has been
uggested to be mediated, at least in part, by a 3-agonistic
ffect (5,38). Furthermore, nebivolol has been suggested to
xert antioxidant effects that have been attributed, at least in
art, to prevent NADPH oxidase activation in response to
yperlipidemia or angiotensin II (9,12). Our data suggest
hat the 3-agonistic effect of nebivolol is involved in the
nhibition of endothelial NADPH oxidase activation.
In the present study, nebivolol improved LV dysfunction
nd survival early after MI, which was not observed with
etoprolol-succinate therapy. In this respect, we and others
ecently showed that both eNOS-dependent NO production
nd NADPH oxidase activation play a pivotal role in LVFigure 3 Cardiac NADPH Oxidase Activity
(A) Reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
activity in remote myocardium in sham-operated and vehicle-, metoprolol-, and
nebivolol-treated mice 4 weeks after surgery as determined by electron spin
resonance spectroscopy analysis (representative ESR spectra are shown in B)
(n  7).ysfunction and survival early after MI (13–17,19). In fact,
WE
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February 1, 2011:601–11 Beneficial Effects of Nebivolol Post-MI Beyond 1-BlockadeFigure 4 LV Weight and Cardiomyocyte Length
(A) Left ventricular (LV) weight/body weight in sham-operated and vehicle-, metoprolol-, and nebivolol-treated mice 4 weeks after surgery. (B) Cardiomyocyte length as
determined from isolated cardiomyocytes (potassium hydroxide method) in sham-operated and vehicle-, metoprolol-, and nebivolol-treated mice 4 weeks after surgery.
(C) Cardiomyocyte length as determined by wheat germ agglutinin staining in sham-operated and vehicle-, metoprolol-, and nebivolol-treated mice 4 weeks after surgery
(representative photographs are shown in D) (n  7).ild-Type Mice: Echocardiographic, Hemodynamic, and Morphometric AnalysesTable 1 Wild-Type Mice: Echocardiographic, Hemodynamic, and Morphometric Analyses
Sham
WT
Vehicle
WT
Metoprolol
WT
Nebivolol
WT
p Value (Metoprolol
vs. Nebivolol)
p Value (Vehicle
vs. Metoprolol)
p Value (Vehicle
vs. Nebivolol)
Echocardiography
EDD, mm 3.8 0.1 6.3 0.3 5.3 0.3 5.2 0.2 NS 0.05 0.01
ESD, mm 2.4 0.1 5.7 0.3 4.9 0.4 4.3 0.2 NS NS 0.01
FS, % 36.7 1.1 9.6 1.7 7.6 3.3 16.6 2.6 0.05 NS 0.05
EF, % 55.9 3.1 18.6 3.7 17.1 5.5 31.7 3.5 0.05 NS 0.05
Weight and morphometric analysis
LV, mg/g body weight 3.6 0.2 6.2 0.5 4.8 0.3 4.0 0.1 0.05 0.01 0.001
Body weight, g 29 1.6 33 1.4 26 0.3 29 0.5 NS 0.001 0.05
LV, mg 105 6 205 21 124 9 114 4 NS 0.001 0.001
Cardiomyocyte cross-sectional area, m2 259 12 553 70 451 8 362 10 0.001 0.01 0.001
Infarct size, % NA 42 3 41 14 41 12 NS NS NS
Systolic blood pressure, mm Hg 110 3 112 2 106 2 104 3 NS NS NS
Heart frequency, min1 598 20 674 15 547 12 553 23 NS 0.01 0.01DD  end-diastolic diameter; EF  ejection fraction; ESD  end-systolic diameter; FS  fractional shortening; LV  left ventricular; NA  not available; WT  wild-type mice.
s
a
n
t
r
a
d
N
e

c

e
e
608 Sorrentino et al. JACC Vol. 57, No. 5, 2011
Beneficial Effects of Nebivolol Post-MI Beyond 1-Blockade February 1, 2011:601–11tatin-induced improvement of LV function and survival early
fter MI were critically dependent on eNOS because they were
ot observed in eNOS-deficient mice (14). Moreover, endo-
helial or cardiomyocyte-targeted overexpression of eNOS
esulted in improved LV function after MI, further suggesting
n important role for eNOS-derived NO production for LV
Figure 5 LV Function
(A and B) LV fractional shortening and LV ejection fraction of sham-treated and po
assessed by echocardiography. (C) Representative photographs of M-mode echoc
cient mice after myocardial infarction treated with vehicle or nebivolol. Abbreviation
NOS-Deficient Mice: Echocardiographic, Hemodynamic, and MorphTable 2 eNOS-Deficient Mice: Echocardiographic, Hemodynami
eNOS/
Sham Vehicle
Echocardiography
EDD, mm 3.8 0.1 5.9 0.5
ESD, mm 2.3 0.1 5.3 0.7
FS, % 39.3 2.6 9.6 1.9
EF, % 60.5 4.3 19.7 3.4
Weights and morphometric analysis
LV, mg/g body weight 3.8 0.1 6.1 0.3
Body weight, g 22 0.8 27 0.5
LV, mg 84 4 162 12
Cardiomyocyte cross-sectional area, m2 337 26 582 16
Infarct size, % NA 49 2
Heart frequency, min1 549 19 562 27
NOS  endothelial nitric oxide synthase; other abbreviations as in Table 1.ysfunction early after MI (13,19). Similarly, drugs that act as
O enhancers have been recently shown to exert beneficial
ffects post-MI (39), however, in the absence of concomitant
-blocker therapy. Based on the present observations, it is
onceivable that enhancement of NO activity in addition to
-blockade provides additive effects early post-MI.
ocardial infarction mice treated with vehicle, metoprolol, or nebivolol as
aphy. (D and E) LV fractional shortening and LV ejection fraction of eNOS-defi-
n Figures 2 and 4.
tric Analysesd Morphometric Analyses
Nebivolol
WT
p Value
(Vehicle eNOS/ vs.
Nebivolol eNOS/)
p Value
(Nebivolol eNOS/ vs.
Nebivolol WT)olol
0.2 5.2 0.2 NS NS
0.2 4.3 0.2 NS 0.05
1.8 16.6 2.6 NS 0.05
3.2 31.7 3.5 NS 0.05
0.4 4.0 0.1 NS 0.05
0.3 29 0.5 NS NS
10 114 4 NS 0.001
11 362 10 0.001 0.05
7 41 12 NS NS
11 553 23 0.05 0.05st- my
ardiogr
s as iomec, an
Nebiv
5.9
5.3
9.6
19.6
5.9
28
167
443
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473
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February 1, 2011:601–11 Beneficial Effects of Nebivolol Post-MI Beyond 1-BlockadeMoreover, in the present study, we observed that nebivo-
ol therapy increased early EPCs and myocardial neovascu-
arization post-MI in an eNOS-dependent manner, which
as not observed in eNOS-deficient mice. The observed
ssociation of an increase in early EPCs, improved myocar-
ial neovascularization, and improved LV function after
ebivolol therapy that were dependent on eNOS does not
rove a cause-and-effect relationship. However, there is
ecent evidence to support the concept that bone marrow–
erived progenitor cells may promote cardiac neovascular-
Figure 6 Survival
Kaplan-Meier survival curves for mice after myocardial infarction (MI) treated with
vehicle, metoprolol, or nebivolol. Percentages of surviving mice are plotted.
Figure 7 Superoxide Production
Electron spin resonance spectroscopy analysis of superoxide production in angiote
Effect of treatment with metoprolol ( ), nebivolol ( ), nadolol ( ), and buprano1 1 1,2 1zation after MI and may contribute to an improved LV
unction after MI. Several recent studies showed that
dministration of ex vivo expanded early EPCs increased
yocardial neovascularization at the infarct border and
mproved LV function (40–43). Cho et al. (43) reported
hat cardiac transplantation of early EPCs stimulated the
ost production of several angiogenic growth factors in the
eri-infarct myocardium. Furthermore, Fazel et al. (44)
bserved that in mice with a mutation of the c-kit receptor,
he mobilization of early EPCs after MI was impaired and
as associated with decreased cardiac neovascularization
nd increased LV dysfunction early after MI. Furthermore,
NOS-derived NO production has been shown to be
ritically important for the mobilization and angiogenic and
ndothelial repair capacity of mobilized early EPCs
14,24,35). More recently, eNOS was observed to be essen-
ial for the effects of bone marrow–derived mononuclear
ells on LV dysfunction after MI, indicating an important
ole of eNOS-containing cells in the effects on cardiac
unction after MI (45). However, several potential local
echanisms have also been suggested whereby increased
NOS-dependent NO availability may improve myocardial
eovascularization including decreased expression of growth
nhibitors (i.e., angiostatin [20]), and improved local vascu-
ar endothelial growth factor expression and activity that
ave been observed after overexpression of eNOS (46).
herefore, it is conceivable that both the eNOS-dependent
I–stimulated human aortic endothelial cells (HAECs).
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Beneficial Effects of Nebivolol Post-MI Beyond 1-Blockade February 1, 2011:601–11ffects of nebivolol therapy on bone marrow–derived pro-
enitor cells and stimulation of local eNOS-dependent
echanisms may have contributed to increased myocardial
eovascularization and the observed beneficial effects on LV
ysfunction early after MI.
In the present study, we observed an inhibition of cardiac
ADPH oxidase activation early after MI in response to
ebivolol, but not metoprolol, therapy. Notably, we and others
ecently demonstrated that prevention of NADPH oxidase
ctivation early after MI by using p47phox or Nox2-deficient
ice attenuated cardiac hypertrophy and improved LV func-
ion and survival (16,17). These studies provide further evi-
ence to suggest that the ancillary properties of nebivolol after
I observed in the present study may be useful in the early
ost-MI period and may provide potentially important bene-
cial cardiac effects beyond conventional -blockade. Further-
ore, our studies on endothelial cells suggest that nebivolol
nhibits endothelial NADPH oxidase activation via its 3-
eceptor–stimulating effect. Although prolonged 1-receptor
lockade has been shown to exert beneficial effects on LV
unction in patients with chronic heart failure and decreased
ystolic function, the present study indicates that nebivolol
ossesses important additional beneficial effects likely indepen-
ent of its 1-receptor blocking action and likely related to its
ffects on eNOS and the NADPH oxidase system in the early
ost-MI period.
tudy limitations. In the present study, we compared the
ffects of nebivolol therapy with those of metoprolol-
uccinate treatment, a selective 1-adrenoreceptor antago-
ist without eNOS-stimulating or NADPH oxidase–
nhibiting properties, on LV dysfunction in mice early after
I, and observed that nebivolol therapy exerts additional
ffects on LV dysfunction early after MI compared with
etoprolol-succinate. As described here, our findings sug-
est that the effects of nebivolol treatment on LV dysfunc-
ion early after MI were dependent on eNOS because there
as no response in eNOS-deficient mice. However, this
oes not exclude that another third-generation -blocker, in
articular carvedilol, may also have ancillary effects, includ-
ng effects on eNOS-derived NO availability that are
elevant for LV dysfunction early after MI. In particular, we
nd others have observed that NADPH oxidase inhibition
as the potential to increase eNOS-dependent NO avail-
bility (22,24). In 2 recent studies, both nebivolol and
arvedilol (at higher concentrations) were observed to in-
ibit NADPH oxidase–dependent superoxide production
n isolated neutrophils (9) and in heart membranes from
ngiotensin II–infused rats (12) that was not detected after
etoprolol or atenolol treatment. Furthermore, carvedilol,
ut not metoprolol, therapy has been observed to improve
ndothelial function in patients with type 2 diabetes (47).
ur findings therefore do not exclude that another third-
eneration -blocker, in particular carvedilol, may also have
ncillary effects on eNOS-dependent NO availability that
re relevant for LV dysfunction and remodeling after MI
hat remains to be determined in future studies and was
eyond the scope of the present study.In the present study, we performed several measurements
f LV hypertrophy post-MI, including determination of the
V weight/body weight ratio, cardiomyocyte length, and
SA because cardiomyocyte hypertrophy post-MI likely
nvolves both, cardiomyocyte lengthening and an increase in
ardiomyocyte width that can be stimulated by increased
echanical stretch and neurohumoral activation (48). The
easurements of cardiomyocyte CSA likely need to be
nterpreted with caution due to potential inherent limita-
ions including analysis from selected representative cross
ections of cardiomyocytes. Although we cannot exclude
hat the cardiomyocyte CSA measurements may have over-
stimated the magnitude of differences between the groups,
verall, the different measurements performed to examine
V hypertrophy in the present study support the notion that
oth -blockers decreased LV hypertrophy post-MI and
hat this effect was more pronounced after nebivolol com-
ared with metoprolol-succinate treatment.
onclusions
he present study provides novel evidence that nebivolol
reatment is associated with beneficial effects on LV dysfunc-
ion, cardiomyocyte hypertrophy, and survival early after MI,
ikely independent of 1-receptor blocking effects because it
as not observed with metoprolol therapy. We speculate that
mproved NO-dependent vasodilation, mobilization of early
PCs, and inhibition of myocardial NADPH oxidase activa-
ion, as observed after nebivolol therapy, but not after meto-
rolol therapy, are contributing underlying mechanisms that
re involved in these beneficial ancillary properties of nebivolol
n the early post-MI period. This notion is supported by the
bservation that nebivolol therapy did not improve LV dys-
unction early after MI in eNOS-deficient mice.
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